A Pharmaceopidemiological Study in Patients Who Use Symbicort Turbuhaler as Maintenance and Reliever Therapy (Symbicort SMART) Capturing Over Use and Under Use Via the General Practice Research Database

AstraZeneca1 个研究点分布在 1 个国家目标入组 1,000 人开始时间: 2007年6月最近更新: 2010年12月1日

适应症

试验速览

阶段: 不适用
状态: 已完成
发起方: AstraZeneca
入组人数: 1,000
试验地点: 1

研究概览研究设计入排标准研究者研究点记录与标识符相似试验

研究概览

简要总结

To investigate how common it is that patients using Symibort SMART take high average daily doses that are not considered appropriate by their physician (overuse) or are hospitalised due to their asthma at least partly due to underuse.

研究设计

研究类型: Observational
观察模型: Case Only
时间视角: Prospective

入排标准

性别: All
接受健康志愿者: 否

入选标准

•Asthma diagnosis, patient registered with the prescribing physician for at least one year before the qualifying prescription of Symbicort, prescription of Symbicort SMART after UK launch of the concept

排除标准

未提供

研究者

发起方

AstraZeneca

申办方类型

Industry

研究点 (1)

Loading locations...

相似试验

已完成

不适用

Symbicort SMART (Symbicort Maintenance And Reliever Therapy)Asthma

NCT00523679AstraZeneca2,000

已完成

1 期

Safety and Tolerability Study of SHP626 in Overweight and Obese AdultsNon-Alcoholic Steatohepatitis

NCT02287779Mirum Pharmaceuticals, Inc.84

已完成

3 期

A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPDChronic Obstructive Pulmonary Disease

NCT00419744AstraZeneca1,200

已完成

3 期

An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent AsthmaAsthma

NCT00419757AstraZeneca558

已完成

不适用

Symbicort Usage in Asthma Treatment and Impact of a New Therapeutic Strategy on Compliance and Asthma Control in FranceAsthma

NCT00812357AstraZeneca579